<DOC>
	<DOCNO>NCT01788696</DOCNO>
	<brief_summary>The purpose study evaluate impact image brain diagnostic tool management early Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Pilot Study To Assess Effect Treatment Adherence PD Subjects</brief_title>
	<detailed_description>The imaging drug use study Ioflupane ( 123I ) Injection , also refer DaTscan . DaTscan FDA approve .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>age 1880 ; diagnosis idiopathic PD exhibit least 2 3 cardinal sign ( bradykinesia , rigidity rest tremor ) ; maximum duration previous exposure antiparkinsonian therapy &lt; 8 week ; ability sign informed consent ; willingness ability complete medication diary questionnaire ; female subject childbearing potential , use effective method contraception . current treatment antiparkinsonian medication ; previous treatment antiparkinsonian medication great 8 week ; inability complete questionnaire ; unwillingness complete questionnaire medication diary ; subject secondary cause parkinsonism ; participant evidence clinical significant thyroid disease , gastrointestinal , cardiovascular , hepatic , renal , hematologic , neoplastic , endocrine , neurologic , immunodeficiency , pulmonary , medical psychiatric disorder ; positive serum/urine pregnancy test time study period ; participant history alcohol , narcotic , drug abuse define DSMIV within past 2 year ; participation concurrent PD trial within 60 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Parkinsonism</keyword>
	<keyword>Idiopathic Parkinson Disease</keyword>
</DOC>